Form 4: Alaunos Director Acquires Shares in Lieu of Fees

Alaunos Therapeutics Director Michael Allen Jerman acquired 4,183 shares of common stock at $3.16 per share, issued in lieu of board fees.

Summary

• Michael Allen Jerman, a Director of Alaunos Therapeutics, Inc. (TCRT), acquired 4,183 shares of the company's common stock.
• The transaction occurred on November 21, 2025, with shares priced at $3.16 each.
• The shares were issued as compensation, specifically in lieu of board fees.
• Following this transaction, Michael Allen Jerman directly beneficially owns 4,183 shares of Alaunos Therapeutics common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, even as compensation, generally indicates a level of confidence in the company's equity. While not a discretionary cash purchase, it aligns the director's financial interests with those of shareholders, which is a moderately positive signal.

Positives

• A director receiving equity as compensation aligns their interests with those of shareholders, indicating confidence in the company's long-term value.
• The use of equity for board fees conserves cash for the company's operations.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The practice of compensating directors with equity, such as common stock in lieu of cash fees, is a standard corporate governance practice across various industries, including biotechnology, to align director incentives with shareholder value creation.

Related Party Transactions

• The transaction involves the issuance of common stock to a director in lieu of board fees, which is a form of related party compensation.

Stakeholder Impact

• Shareholders may view the director's acceptance of equity compensation as a positive sign of commitment and belief in the company's future.
• The company benefits from conserving cash by issuing equity for board fees.

Key Dates

Recommendation

The acquisition of shares by a director in lieu of board fees is a common form of equity compensation, indicating alignment of interests with shareholders. While it reflects confidence in the company's equity, it is not a discretionary open market purchase and thus does not provide a strong signal for a 'buy' or 'sell' recommendation. Investors should consider this as a standard governance practice rather than a strong market indicator.

Keywords

Alaunos Therapeutics, TCRT, Michael Allen Jerman, Director, Insider Transaction, Form 4, Share Acquisition, Equity Compensation, Board Fees, Rule 10b5-1